Add to Calendar 9/9/2019 10:00:00 AM 9/9/2019 5:00:00 PM Digital Health Impact 2019

Online registration is now closed, there will be a limited number of onsite registrations on Monday

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our inaugural Digital Health Impact 2019 event at the InterContinental Boston at 510 Atlantic Ave, Boston, MA 02210, part of Biotech Week Boston, as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients. Contact Laura Rudberg for sponsorship opportunities. View our sponsorship prospectus here

Intercontinental Boston, 510 Atlantic Avenue, Boston MA, 02210
President & CEO, InCarda Therapeutics, Inc.
Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she serves on the board of directors of ProterixBio (Executive Chairman; formerly CEO), CareDx (NASDAQ:CDNA) and Cocoon Biotech, and formerly on the boards of Paradigm Diagnostics and PerceptiMed. She was also formerly a Partner and Senior Advisor at New Science Ventures, a NY-based venture capital firm with over $700M under management, and held executive and managerial roles at Intrexon Corporation, Gilead Sciences, Affymetrix, the International Genomics Consortium and McKinsey & Co. Dr. Colón received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering.

Brought to you by